Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.

J M. Bland, D. G Altman, Multiple significance tests: the Bonferroni method BMJ. ,vol. 310, pp. 170- 170 ,(1995) , 10.1136/BMJ.310.6973.170

E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25

Martha Nowosielski, Matthew D. DiFranco, Daniel Putzer, Marcel Seiz, Wolfgang Recheis, Andreas H. Jacobs, Günther Stockhammer, Markus Hutterer, An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0095830

Andreas Stadlbauer, Petra Pichler, Marianne Karl, Sebastian Brandner, Claudia Lerch, Bertold Renner, Gertraud Heinz, Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy European Journal of Radiology. ,vol. 84, pp. 1128- 1136 ,(2015) , 10.1016/J.EJRAD.2015.02.025

Aurélien Corroyer-Dulmont, Elodie A. Pérès, Aurélie N. Gérault, Ariel Savina, Fanny Bouquet, Didier Divoux, Jérôme Toutain, Méziane Ibazizène, Eric T. MacKenzie, Louisa Barré, Myriam Bernaudin, Edwige Petit, Samuel Valable, Multimodal imaging based on MRI and PET reveals [ 18 F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 43, pp. 682- 694 ,(2016) , 10.1007/S00259-015-3225-0

M. Hutterer, M. Nowosielski, D. Putzer, D. Waitz, G. Tinkhauser, H. Kostron, A. Muigg, I. J. Virgolini, W. Staffen, E. Trinka, T. Gotwald, A. H. Jacobs, G. Stockhammer, O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma The Journal of Nuclear Medicine. ,vol. 52, pp. 856- 864 ,(2011) , 10.2967/JNUMED.110.086645

C. Colavolpe, O. Chinot, P. Metellus, J. Mancini, M. Barrie, C. Bequet-Boucard, E. Tabouret, O. Mundler, D. Figarella-Branger, E. Guedj, FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan Neuro-oncology. ,vol. 14, pp. 649- 657 ,(2012) , 10.1093/NEUONC/NOS012

N. Galldiks, K.-J. Langen, R. Holy, M. Pinkawa, G. Stoffels, K. W. Nolte, H. J. Kaiser, C. P. Filss, G. R. Fink, H. H. Coenen, M. J. Eble, M. D. Piroth, Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI The Journal of Nuclear Medicine. ,vol. 53, pp. 1048- 1057 ,(2012) , 10.2967/JNUMED.111.098590

Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W.K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy, Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma Journal of Clinical Oncology. ,vol. 27, pp. 4733- 4740 ,(2009) , 10.1200/JCO.2008.19.8721

Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin JB Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger, Peter Hau, Alba A Brandes, Johanna Gijtenbeek, Christine Marosi, Charles J Vecht, Karima Mokhtari, Pieter Wesseling, Salvador Villa, Elizabeth Eisenhauer, Thierry Gorlia, Michael Weller, Denis Lacombe, J Gregory Cairncross, René-Olivier Mirimanoff, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncology. ,vol. 10, pp. 459- 466 ,(2009) , 10.1016/S1470-2045(09)70025-7